US pharmaceutical giant Eli Lilly has announced plans to invest over $1bn (Rs 9000 crores) in Telangana, India.

Eli Lilly will make this investment over the next several years, primarily into new contract manufacturing. This strategic investment will further strengthen the company's manufacturing and supply capabilities.

It will also establish a new manufacturing plant and quality centre in Hyderabad as part of this strategy. The new facility will provide advanced technical support and oversight for its contract manufacturing network across India.

Additionally, recruitment for the new facility will start immediately, offering opportunities for engineers, chemists, analytical scientists, quality assurance experts, and management professionals.

Patrik Jonsson, executive vice president and president of Lilly International, Eli Lilly and Company, highlighted that the firm is investing in manufacturing and increasing supply worldwide.

"Working with trusted contract manufacturers expands our capabilities to deliver life-changing medicines at greater scale— with quality always at the core," he added.

Sridhar Babu Duddilla, Minister of IT for Telangana, credited Telangana’s strong industrial ecosystem for this investment decision.

“Eli Lilly’s expansion will create thousands of high-value jobs and further strengthen Hyderabad’s status as the nation’s pharma hub. With progressive policies and clear government support, Telangana is poised to become a global leader in pharma innovation and opportunity,” he added.